Concepedia

Publication | Open Access

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

DOIFull Paper Access

268

Citations

18

References

2019

Year

James F. Howard, Vera Bril, Ted M. Burns, Renato Mantegazza, Małgorzata Bilińska, Andrzej Szczudlik, Said R. Beydoun, Francisco Javier Rodríguez de Rivera Garrido, Fredrik Piehl, Mariarosa Rottoli,
Neurology

Abstract

This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.

References

YearCitations

Page 1